Skip to main content
OpenTrials
Completed

NCT Number: NCT05027997

Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm

This study is designed to assess the safety and tolerability of dipraglurant in patients with blepharospasm (BSP) (randomized 1:1:1 to receive dipraglurant 50 mg, 100 mg or placebo) and explore the efficacy of 50 mg and 100 mg immediate release tablets (versus placebo) on the severity and frequency of BSP signs and symptoms using objective measures, clinical ratings and patient reported outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Blepharospasm Dyskinesias Dystonia Eye Diseases Eyelid Diseases Nervous System Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Emory University

Atlanta, Georgia, 30329, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with an established diagnosis of idiopathic benign essential blepharospasm
  • Must have had prior response to to botulinum toxin (BoNT) reported on last 2 consecutive injection cycles
  • Last injection of BoNT at least 8 weeks prior to Screening assessments
  • Patient is experiencing features of Blepharospasm (BSP) of moderate severity/frequency at study entry.

Exclusion criteria

  • BSP that is known or suspected to be associated with a known cause such as neuroleptic exposure, brain injury or lesion, stroke, Parkinson's disease, or related Parkinsonisms
  • History of surgical intervention (e.g., deep brain stimulation) or orbital myectomy for dystonia
  • Disabling eyelid opening apraxia
  • Other neurological disease (including psychiatric disease and/or cognitive impairment) that, in the opinion of the investigator, would affect the patient's ability to complete study assessments.
  • Other significant medical condition that may affect the safety of the patient or preclude adequate participation in the study.

Other protocol-defined inclusion and exclusion criteria may apply

Treatment and study plan

Dipraglurant

Drug

Oral tablet

Other names: ADX48621

Placebo

Drug

Oral matching placebo tablet

Primary outcomes

  1. Safety and tolerability of dipraglurant as measured by incidence of adverse events

    Time frame: Baseline to Day 2

    The primary outcome will be testing the safety and tolerability of dipraglurant in patients with blepharospasm based on the incidence of adverse events reported by patients and/or as identified by the Investigator based on clinical assessments conducted during the study.

  2. Computerized Motor Objective Rater (CMOR) analysis of blinking activity

    Time frame: Baseline to Day 2

    Video analysis, by an independent rater, of the mean proportion of eye closure time, severity of periocular spasms, and blink rate. Decreased eye closure time, severity of periocular spasms and blink rate indicates improvement of blepharospasm symptoms.

  3. Skintronics wearable analysis of blinking activity

    Time frame: Baseline to Day 2

    Analysis of blinking activity as recorded on the Skintronics wearable device. Decreased blink activity indicates improvement of blepharospasm symptoms.

Secondary outcomes

  1. Jankovic Rating Scale (JRS) severity score

    Time frame: Baseline to Day 2

    The JRS is a clinician rated scale for blepharospasm. The intensity of eyelid spasms is measured based on a 5 point grading system where 0 indicates no symptoms and 4 indicates the most severe symptoms.

  2. Jankovic Rating Scale (JRS) frequency score

    Time frame: Baseline to Day 2

    The JRS is a clinician rated scale for blepharospasm. The frequency of eyelid spasms is measured based on a 5 point grading system where 0 indicates no symptoms and 4 indicates highest frequency symptoms.

  3. Global Dystonia Severity Rating Scale (GDS)

    Time frame: Baseline to Day 2

    The GDS is a clinician rated scale for the assessment of dystonia severity across multiple body regions. Each body region is rated on a scale from 0-10 where 0 represents no dystonia and 10 represents severe dystonia.

  4. Blepharospasm Phenotyping Tool (BPT)

    Time frame: Baseline to Day 2

    The BPT is a clinician rated scale assessing 4 major phenotypic elements of blepharospasm using a 4 point scale for severity and frequency, where 0 indicates no symptoms and 4 indicates the highest frequency and/or most severe symptoms.

  5. Blepharospasm Severity Rating Scale (BSRS)

    Time frame: Baseline to Day 2

    The BSRS is a clinician rated scale for rating severity of blepharospasm based on 6 clinical features of the condition. A total score is generated based on the combined score for severity and frequency and where a higher value indicates more severe symptoms.

  6. Clinician's Global Impression of Severity (CGI-S) score

    Time frame: Baseline to Day 2

    The CGI-S score is used by the Investigator to determine, in a global sense, how severe the patients blepharospasm is in the context of other blepharospasm patients. Increased scores indicate more severe symptoms.

  7. Blepharospasm Disability Index (BSDI)

    Time frame: Baseline to Day 2

    The BSDI is a 6 item patient rated disability scale that measures how blepharospasm effects activities of daily living. Each item is scored on a 5 point scale to produce a total score of up to 30, where a higher individual item score and a higher total score indicate greater disability to the patient.

  8. Patient Global Impression of Change (PGI-C) score

    Time frame: Baseline to Day 2

    The PGI-C score is a patient reported outcome that assesses how much the blepharospasm symptoms have improved or worsened. A score of 0 indicates no change, negative scores down to -3 indicate worsening, and positive scores of up to 3 indicate improvement.

Sponsors and collaborators

Lead sponsor

Addex Pharma S.A.

Industry

Registry information

Official study title

Exploratory Phase 2a Randomized, Double-blind, Placebo-controlled Study of Dipraglurant (ADX48621) Immediate Release Tablets in Patients With Blepharospasm

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Aug 31, 2021
Registry last updated
Oct 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.